• Home
• Directors
  • Current
  • Past
• Core Facilities
  • Clinical
  • Genomics
  • Biofilm
  • Cell culture
• Projects
  • Current
    • MicroRNAs and Chronic Allograft Rejection after Lung Transplantation
    • Epithelial-leukocyte interactions
  • Past
    • Adaptive significance of LasR mutations
    • Genetic determinants of biofilm formationUntitled Item
• Fellows
  • Current
  • Past
• Links
• News
• Contact

UW CFF RDP News

Another Successful CF Research Retreat

Our annual retreat was held August 29 with about 60 participants. By all accounts it was an interesting and informative day with excellent talks all around. The day included a keynote talk by Dr. Michael Welsh on CFTR, biocarbonate secretion and pH in the CF lung, and a panel discussion on what CF researchers should be thinking about with the advent of new drugs targeting the basic defect.

There were awards! We celebrated Moria Aiken who received the 2012 CFRI Professional-of-the-Year award. Below is a picture of our very own Moira receiving the award in Palo Alto, CA.

This year, for the first time, we awarded the Charlie Moore CF Microbiology Fellowship. The recipient is Dr. Ben Staudinger, a Fellow, who is developing his own research program with mentoring from Dr. Pradeep Singh. Below is a picture of Ben with Charlie Moore's son, Chad, and Chad's living children, Ladd and Mackenzie. The picture Chad is holding is of Charlie Moore and his granddaughter Lizzie, a victim of CF. The Moores are tireless supporters of the CF Foundation and CF research at the UW.

New Requirement for CFF Research Grants and Pilot & Feasibility Awards

From: <grants@cff.org>
Date: May 29, 2009 8:00:07 AM PDT
To: <grants@cff.org>
Subject: CFF Basic Research Letter of Intent

Dear Principal Investigators:

In an effort to improve our review process for Research Grants and Pilot & Feasibility Award, we will be requiring a Letter of Intent (LOI) from investigators who wish to submit an application for these grant types. We have initiated this step due to the high number of grant applications typically received and to reductions in CFF’s medical/scientific budget as a result of the economy. By soliciting LOIs, we hope to avoid unnecessary time spent by investigators preparing grants and by CFF staff and reviewers in examining these applications. Funding priority will be placed on those projects proposing to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat it.

Attached are the LOI guidelines. LOIs must be submitted electronically at Proposal Central -https://proposalcentral.altum.com/. The deadline for LOI submissions is July 1, 2009. Applicants will be notified in early August whether or not their LOI has been accepted for a full grant submission. If accepted, applications will be due by the first Wednesday of October.

Should you have any questions, please feel free to contact the Grants and Contracts Office at grants@cff.org. Thank you and have a wonderful weekend.

Regards,
Deb

Deb Jurmu
Grants and Contracts Manager
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814

The Seattle Great Strides Walk for a Cure was held Sunday May 17, 2009. Donations are still coming in and the walk is on target to raise $400,000 for CF Foundation supported research! Special thanks to Gilead the presenting sponsor for $30,000, Ramsey's Racers, over $18,000, and the UW Chapter of Gamma Phi Sorority, $8,000. It was a beautiful, sunny Seattle day, and as usual the walk looped through Bell Town, along the water front, and back to the Seattle Center for a BBQ lunch.

April 28, 2009: Caroline Harwood, member of the UW CF RDP, elected to membership in the National Academy of Sciences

Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis